Demonstrating that the best solution is not always a multistage approach, a new trial showed catheter ablation is superior to a combination of antiarrhythmic drugs and lifestyle changes — weight loss, ...

Patients with structural heart disease are at risk for life-threatening ventricular tachycardias (VTs). Implantable cardioverter-defibrillators (ICDs) can terminate VT, but often at the cost of ...

A catheter ablation procedure widely used to treat the most common heart rhythm disorder significantly reduces the burden of atrial fibrillation (AF) and results in clinically important improvements ...

Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased ...

Augusta Health now offers the Abbott Volt Pulsed Field Ablation System as a safer option for treating AFib patients.

Cardiac arrhythmias are a leading cause of morbidity and mortality worldwide. Catheter ablation provides a minimally invasive means to target and eliminate arrhythmogenic substrates within the heart.

For patients with atrial fibrillation, catheter ablation reduces the risk of ischemic stroke at more than 30 days, mortality, and heart failure hospitalization, while surgical ablation only reduces ...

Compared with medical therapy, rhythm control with catheter ablation is associated with lower risk of ischemic stroke after 30 days, as well as less mortality and heart failure (HF) hospitalization, ...

An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace and presented at EHRA 2024. Lead author Dr. Stylianos ...

Please provide your email address to receive an email when new articles are posted on . In patients with atrial fibrillation, catheter ablation reduces anxiety and depression symptoms better than ...

LONDON, England—The impact of pulmonary vein isolation (PVI)—the mainstay of catheter ablation for atrial fibrillation (AF)—should not be attributed to placebo effects, according to the SHAM-PVI trial ...